Previous 10 | Next 10 |
Under Priority Review status, the FDA has accepted for review Horizon Therapeutics' ( HZNP -2.6% ) marketing application for teprotumumab for the treatment of active thyroid eye disease. More news on: Horizon Therapeutics Public Limited Company, Healthcare stocks news, Read more .....
The FDA grants Priority Review Designation to Horizon Therapeutics' (NASDAQ: HZNP ) BLA for teprotumumab, an investigational medicine for the treatment of active thyroid eye disease (TED). More news on: Horizon Therapeutics Public Limited Company, Healthcare stocks news, Read more .....
-- If Approved, Teprotumumab Would be the First FDA-Approved Medicine for this Vision-Threatening Disease -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for teprotumumab, ...
This article is part of a series that provides an ongoing analysis of the changes made to John Paulson's 13F stock portfolio on a quarterly basis. It is based on Paulson's regulatory 13F Form filed on 08/14/2019. Please visit our Tracking John Paulson's Paulson & Company Portfolio serie...
- Current Executive Vice President and Chief Business Officer, Robert F. Carey, will Retire Effective Oct. 1. - DUBLIN – August 28, 2019 – Horizon Therapeutics plc (Nasdaq: HZNP) today named Andy Pasternak executive vice president, chief business officer, reporting direct...
A rigorous evaluation of the state of care for thyroid eye disease (TED) published in the American Journal of Ophthalmology (AJO) highlights the lack of current therapies to adequately treat the disease. The invited ‘Perspective’ discusses the potential for Horizon’s ...
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the company will participate in the following conference in September: Morgan Stanley 17 th Annual Global Healthcare Conference Date: Sept. 10, 2019 Presentation Time: 10 a.m. ET Location: New York The c...
-- New website features resources, transitions support and personal stories of people living with rare diseases -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced the launch of RAREisCommunity.com , a go-to resource for the more than 350 million people around the world living ...
Horizon Therapeutics Public Limited Company (HZNP) Q2 2019 Results Conference Call August 07, 2019 08:00 AM ET Company Participants Tina Ventura - VP, IR Tim Walbert - Chairman, President and CEO Shao-Lee Lin - EVP, Head R&D and Chief Scientific Officer Paul Hoelscher - EVP...
The following slide deck was published by Horizon Therapeutics Public Limited Company in conjunction with their 2019 Q2 earnings Read more ...
News, Short Squeeze, Breakout and More Instantly...
Horizon Therapeutics Public Limited Company Company Name:
HZNP Stock Symbol:
NASDAQ Market:
Horizon Therapeutics Public Limited Company Website:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Horizon Therapeutics Public Limited Company (HZNP) is expected to report $1.22 for Q3 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOM...